Research on the biology of tumor cells. Covers tumor spread, cell-particle diagnostics, new anti-tumor molecules, and cancer-killing immune cells.
A new BGU study identifies a molecular switch that controls stressed cell survival or death, revealing a redox-driven tipping point. The research provides crucial mechanistic insights into overcoming chemotherapy resistance in aggressive tumors.
A new device uses electricity to separate cancer-associated signals from healthy particles in the blood, offering a new method for studying pancreatic cancer. The device, which sorts particles based on their electrical charge, showed promise in distinguishing cancer samples from healthy ones.
Researchers at ISTA discover that chaotic environments around tumor cells can trigger specific behavior, leading to increased detachment and invasion. Computer simulations and experiments confirm the findings, shedding new light on the complex interactions between cancer cells and their microenvironment.
Researchers developed small molecules that activate macrophages to attack cancer cells, weakening the tumor's defenses against the immune system. The molecules, called Phagocytic Synapse Enhancers, were tested in cell cultures and animal models and showed promising results, slowing tumor growth and extending survival.
A study found that supercentenarians, people who live to 110 and beyond, have a higher proportion of cancer-killing immune cells called CD4 CTLs. This expansion may help the immune system adapt to age-related challenges, contributing to exceptional longevity.
WPI researchers develop new models to study uterine fibroids with NIH funding, building on student projects. The models will help researchers better understand and develop treatments for fibroids, which affect millions of women.
A single-cell atlas reveals that a balance between two macrophage states, with lipid-fueled immunesupressors, tracks clinical outcomes in gastric cancer patients. Tumors with a more permissive immune state respond better to immunotherapy and have longer progression-free survival.
Researchers found that eustress reduces CCL2 expression, alleviating cardiac damage and enhancing chemotherapy response. Eustress also remodels the tumor immune microenvironment, increasing cytotoxic CD8⁺ T cells and anti-tumor M1-type macrophages.
Researchers developed an AI-assisted technique to identify and treat malignant brain tumors by targeting multiple arterial pedicles. The approach successfully covered over 85% of each tumor in three patients, reducing delivery outside the intended treatment area.
Researchers developed nanoparticles that retain their protective coating in normal tissue but shed it upon reaching tumor tissue, releasing anticancer drugs. This technology reduces systemic side effects and enhances treatment efficacy.
Researchers developed an AI platform, CANVAS, to predict cellular neighborhoods and their relationships in tumor tissues. The platform identified 10 discrete neighborhoods, including those rich in immune cells and associated with poorer outcomes and reduced responsiveness to immunotherapy.
Researchers at IISc discovered that low-frequency ultrasound can selectively target and kill oral cancer cells, while leaving healthy tissues unharmed. This approach uses moderate mechanical forces to damage cancer cells beyond their ability to recover, potentially leading to safer treatment strategies for oral cancer.
Researchers develop cellular model to reproduce NF1-associated tumour progression, identifying new therapeutic opportunities. The combination of olaparib and selumetinib shows promise in reducing tumour growth.
A molecule called Sindecam-4 (SDC4) on cell surfaces may help prevent tumor progression and metastasis. Silencing the receptor halted accelerated growth of tumor cells, causing them to resume responding to natural programmed cell death mechanisms.
Researchers discovered that engineered nanoparticles directly induce tumor-cell death while transforming the immune microenvironment, supporting further investigation of their therapeutic potential. The particles push cancer cells toward ferroptosis and convert inert immune cells into robust antitumor activity.
Researchers at UCSF built a robotic system to treat thousands of mini tumors, identifying shared features among persister cells that could help explain why cancer comes back. Nine drugs consistently weakened persister cells, suggesting common vulnerabilities.
Researchers have developed a new method that can detect cancer with low levels of DNA in the blood, providing more detailed information about tumour composition. This could lead to better care for cancer patients, enabling closer monitoring of treatment progress and more informed decision-making.
A University of Ottawa-led study has discovered a hidden network driving glioblastoma's aggressive growth, highlighting a promising target for next-generation therapies. The research reveals that a protein called OSMR plays a critical role in tumor progression and supports the survival of brain tumour stem cells.
Research in flies shows that tumor cells with chromosomal instability can become senescent and release signals altering neighboring tissue behavior. This process promotes tumor growth by inducing the death of nearby healthy cells.
Researchers found that a vitamin D analog reduced fibroblast activation and increased T cell infiltration in pancreatic tumors, improving chemotherapy responses and progression-free survival. Patients with high vitamin D receptor expression also had longer overall survival.
The review outlines a comprehensive understanding of the chemokine and receptor network in the tumor microenvironment, introducing a novel 3D targeting framework to guide precision combination immunotherapies. The proposed
Researchers found that self-propelled particles can spontaneously form clusters when navigating a dense colony of dividing cells. The growing medium creates an environment that transforms the particles' behavior, making them behave like active Brownian particles and attracting them to each other without explicit interaction.
Researchers have developed a drug carrier that physically anchors itself to cancer cell membranes, improving drug retention and effectiveness. The technology maximizes tumor delivery of drugs while sparing normal tissues, resulting in safer and more effective therapies.
Researchers developed RegVelo, an AI framework that models cellular dynamics and gene regulation to predict cellular fate decisions. The model traces developmental trajectories and simulates regulatory interactions, providing insights into hidden drivers of development and potential therapeutic targets.
Researchers developed a blood test that identifies nine cellular neighborhoods surrounding tumors, correlating with tumor response to immunotherapy and patient prognosis. The test provides real-time access to information about successful therapies.
A new study reveals that impaired protein recycling is the key factor in T cell exhaustion, allowing researchers to develop a 'tag and sort' fix to restore normal proteostasis. This approach boosts the potency of cell therapy against cancer.
A team of researchers has developed a 'tumor-on-a-chip' system designed to recreate the complex environment surrounding pancreatic tumors. The system, which combines patient-derived organoids with microfluidic technology, closely mimics the behavior of human pancreatic tumors and demonstrates potential for studying immune responses.
Researchers developed a cancer assessment tool that can identify high-risk patients and specific cell populations linked to their risk. The tool, called scSurvival, predicts survival outcomes more accurately than traditional methods by analyzing single-cell data at cellular resolution.
Researchers have identified the Prrx1 gene as a key regulator of metastatic potential in breast cancer tumors. This discovery helps explain why highly invasive cells do not always give rise to metastases, and how cells combine invasiveness and proliferation to become the most dangerous from a clinical perspective.
A Johns Hopkins study reveals that cysteine metabolism shapes CD8+ T-cell function, with implications for boosting cancer-killing immune responses. Limiting cysteine in laboratory models enhanced anti-tumor immunity but impaired T-cell expansion and weakened anti-tumor activity.
A study by researchers at Institute of Science Tokyo has identified a key gene, DOCK10, involved in abnormal insulin secretion in insulinomas. The findings pave the way for novel diagnostic biomarkers and treatment options.
Researchers developed GluBs to target ASCT2 in aggressive cancers, bypassing the LAT1 route. The agents showed efficacy in limiting tumor growth and demonstrating potential to treat cancers with limited LAT1 expression.
Researchers found that dual-positive cells, a type of circulating tumor cell, are associated with shorter survival times and increased risk of metastasis in patients with advanced breast cancer. The study highlights the potential importance of these under-studied cells in breast cancer progression.
New research reveals that tumor cells in supratentorial ependymomas cluster into distinct neighborhoods, each with a specific role, such as proliferating or invading. Understanding these cell subtypes could help predict treatment response and inform targeted therapies for this aggressive childhood brain cancer.
A study reveals that senescence plays a paradoxical role in postpartum breast cancer, promoting tumor formation while also aiding tissue repair. Targeting senescent cells during mammary gland involution could potentially reduce the risk of this form of cancer.
Researchers have genetically engineered therapeutic CAR T cells that can destroy solid tumors, overcoming a major obstacle in cancer treatment. By silencing prostaglandin E2 signalling, these new cells can recognize and attack cancer cells without suppressing their own immune function.
SLAMF6 is a molecule on the surface of immune cells that prevents T cells from effectively attacking tumours. Researchers have developed new monoclonal antibodies that prevent SLAMF6 from interacting with itself, potentially offering an option for patients who no longer respond to PD1 or PDL1 treatments.
A new study reveals the CDK12-FOXA1-MDM2-p53 signaling axis promotes prostate cancer development through FOXA1 modification. The study identifies S234 phosphorylation as a critical site, and a CDK12 inhibitor THZ531 effectively blocks this pathway, reducing tumor growth.
Scientists at UNIGE created an AI tool called MangroveGS that can accurately predict the risk of cancer metastasis and recurrence. The algorithm uses gene expression signatures from colon cancer cells to identify key factors influencing metastatic potential, paving the way for more precise care and discovery of new therapeutic targets.
Researchers found that TL1A, a key immune signaling protein, stimulates the growth of new white blood cells in the bone marrow, which then promote tumor formation in the gut. The study suggests that blocking TL1A activity could be an effective strategy to treat IBD and prevent associated colorectal tumors.
Cancer researchers have identified a key mechanism by which cancer cells protect themselves from the immune system. The study found that MYC protein can bind to RNA molecules, eliminating alarm signals that would activate the immune defense.
Active aldehydes promote toxic lipid peroxidation, impairing FAO and activating glycolysis in killer T cells, accelerating exhaustion. This vicious cycle exacerbates T cell differentiation and dysfunction.
A new consensus classifier for pancreatic cancer has been developed, enabling accurate determination of tumor subtypes and informing treatment choices. The tool also identifies risk factors for the disease, including smoking, which may be more significant in certain subtypes.
Researchers discovered glioblastoma cells use PRDM9 to survive chemotherapy and regrow tumors. By blocking PRDM9 or cutting off cholesterol supply, persister cells can be wiped out, improving survival in mice. This breakthrough offers new strategies for treating the deadliest brain cancer.
Researchers have identified two proteins that allow cancer cells to evade destruction by brain immune cells, known as microglia. By removing these proteins, microglia play a key role in eliminating cancer cells during the early stage of their arrival in the brain.
Scientists at Penn Vet have identified two genes, Ctnna1 and Bcl2l13, that suppress metastasis in preclinical models of colorectal cancer. These findings could lead to better treatments and therapies for patients with metastatic disease.
Researchers at UNIGE and HUG have developed CAR-T cells capable of destroying glioblastoma cells by targeting specific proteins present in the tumour environment. The new approach has shown promising results in animal models, paving the way for clinical trials in humans.
Researchers analyzed 29 new and 22 previously reported cases of PCNSL involving the ventricles, finding different clinical symptoms such as headache, dizziness, and vision impairment. The study suggests that despite its unusual location, ventricular PCNSL behaves like other forms of brain lymphoma, with a recommended treatment strategy...
Biomechanical forces play a crucial role in regulating cancer invasion and metastasis by modulating cell membrane topology, actin cytoskeletal remodeling, and mechanical stress adaptation. The review highlights the importance of three-dimensional tumor models and novel therapies targeting mechanical signaling pathways to inhibit invasion.
A recent review in the Chinese Medical Journal uncovers how circulating tumor cells evade immune elimination, highlighting their interactions with immune cells and blood components. The study suggests new therapeutic targets, including anti-platelet therapy and immune checkpoint inhibitors, to combat cancer metastasis.
Researchers at Rice University have engineered living cells to use a 21st amino acid that illuminates protein changes in real time, providing a new perspective on the inner workings of life. This breakthrough addresses a long-standing challenge in biology by allowing scientists to track subtle protein changes within living systems.
A team of researchers identified a unique protein signature that can predict which patients are likely to resist standard therapies, paving the way for personalized treatments. By blocking a specific transporter system, they made tumors more sensitive to treatment, suggesting a promising new avenue for treating colorectal cancer.
Researchers developed a novel technology to attach 'fake targets' to tumor cells, enabling immune cells to attack regardless of antigen presence. The Univody platform showed promising results in animal models, suppressing tumor growth and triggering broader immune activation.
The study identified chemical compounds that precisely block the interaction between RAS and a key pathway for tumour growth. The treatment has entered its first clinical trial in humans and has shown promising results, with potential to treat many different types of cancers while avoiding effects on healthy cells.
A team at Lund University has discovered a surface protein, SLAMF6, that helps leukemia cells evade the immune system. The researchers developed an antibody to block this mechanism, restoring the immune system's ability to kill cancer cells in laboratory trials and mice.
Researchers have discovered myeloid cells in children's liver tumors that could be activated for treatment. This discovery provides new avenues for immunotherapy in childhood liver cancer.
Researchers developed a new strategy to boost immunotherapy in solid tumors by targeting senescent immune cells, which contribute to treatment resistance. The approach showed improved efficacy and lower toxicity compared to existing treatments.
Researchers developed an engineered strain of gut-homing bacteria that induces mature tertiary lymphoid structures, associated with improved survival and stronger treatment responses. The therapy also restored healthy gut microbiota and showed excellent biocompatibility.
Researchers develop antibody-γδ T cell conjugates to target PD-L1-positive cancers, inducing pyroptosis and remodeling tumor microenvironment. This dual action promotes direct killing of cancer cells and sustained anti-tumor immunity.
Researchers at Graz University of Technology created a highly detailed digital twin of the A549 lung cancer cell line, paving the way for individualized cancer treatment. The model simulates calcium dynamics and electrical voltages, allowing for testing of drugs and personalized treatment strategies.